Nature Search

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

In the randomized phase 3 AMPLITUDE trial, patients with HRR-deficient mCSPC experienced longer progression-free survival when they were treated with niraparib and AAP compared to placebo and AAP.

Gerhardt Attard
Neeraj Agarwal
Dana E. Rathkopf
ResearchOpen Access07 Oct 2025
Nature Medicine

P: 1-10
Envisioning the future of early anticancer drug development

There is an urgent need to accelerate the development of new molecularly targeted cancer therapeutics by improving early clinical anticancer drug evaluation. This article discusses current approaches and new strategies that should maximize benefit to patients and expedite the regulatory approval of new anticancer drugs.

Timothy A. Yap
Shahneen K. Sandhu
Johann S. de Bono
Reviews10 Jun 2010
Nature Reviews Cancer

Volume: 10, P: 514-523
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer

The epigenetic mechanisms underlying phenotypic diversity across different metastatic sites in castration-resistant prostate cancer (CRPC) remain to be characterised. Here, multi-omic profiling across metastatic lesions identifies regulatory networks driving tumour lineage programs and potential therapeutic targets.

Kei Mizuno
Sheng-Yu Ku
Himisha Beltran
ResearchOpen Access01 Jul 2025
Nature Communications

Volume: 16, P: 1-13
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

In a post-hoc analysis of circulating tumor DNA (ctDNA) features from patients with metastatic prostate cancer treated with [¹⁷⁷Lu]Lu–PSMA-617 or cabazitaxel in the randomized phase 2 TheraP trial, low ctDNA levels at baseline were predictive of clinical benefit from [¹⁷⁷Lu]Lu–PSMA-617, and PTEN or ATM alterations were identified as potential biomarkers of response.

Edmond M. Kwan
Sarah W. S. Ng
Alison Y. Zhang
Research27 May 2025
Nature Medicine

Volume: 31, P: 2722-2736
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer

Oral poly(ADP)-ribose polymerase (PARP) inhibitors have been shown to have great promise in the treatment of cancer inBRCA mutation carriers. This case provides evidence that these agents are efficacious in patients with PTEN deficiency but no BRCAmutations, opening up a new patient cohort for this treatment.

Martin D. Forster
Konstantin J. Dedes
L. Rhoda Molife
Reviews05 Apr 2011
Nature Reviews Clinical Oncology

Volume: 8, P: 302-306
Unravelling mutational signatures with plasma circulating tumour DNA

Accurately detecting cancer mutational profiles from circulating tumour DNA (ctDNA) remains a challenging task. Here, the authors develop MisMatchFinder, an algorithm that can detect mutational signatures in shallow whole-genome sequencing data from ctDNA across multiple cancer types.

Sebastian Hollizeck
Ning Wang
Sarah-Jane Dawson
ResearchOpen Access14 Nov 2024
Nature Communications

Volume: 15, P: 1-9
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology

The prognosis of castration-resistant prostate cancers remains dismal, but accurate preclinical models can lead to effective therapies. Here the Melbourne Urological Research Alliance establish prostate cancer patient-derived xenografts, use the tumors for organoids and single-cell RNA-seq, and show the efficacy of PARP inhibitor combination treatments.

Gail P. Risbridger
Ashlee K. Clark
Renea A. Taylor
ResearchOpen Access19 Aug 2021
Nature Communications

Volume: 12, P: 1-17
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones

The heterogeneity of androgen receptor (AR) gene alterations across metastases in prostate cancer remains unresolved. Here, the authors characterise AR genomic complexity across spatially separated lethal metastases from 10 prostate cancer patients and investigate how AR alterations evolve.

A. M. Mahedi Hasan
Paolo Cremaschi
Gerhardt Attard
ResearchOpen Access10 Aug 2023
Nature Communications

Volume: 14, P: 1-16
Spatial analysis with SPIAT and spaSim to characterize and simulate tissue microenvironments

Spatial proteomic data serve to provide cell-level location information for the extraction of biological features from tissues, but analyzing such data can be difficult. Here the authors report the development of SPIAT for data analyses and spaSim for simulation and validation of methods to help bridge the gap between the technology and its translation.

Yuzhou Feng
Tianpei Yang
Anna S. Trigos
ResearchOpen Access15 May 2023
Nature Communications

Volume: 14, P: 1-20
Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling

The genetic changes that occur in late stage metastatic melanoma are not well delineated. Here, the authors use rapid autopsy samples from metastatic melanoma patients and show that the late stage in the disease is characterised by whole genome doubling and aneuploidy.

Ismael A. Vergara
Christopher P. Mintoff
Mark Shackleton
ResearchOpen Access04 Mar 2021
Nature Communications

Volume: 12, P: 1-15
The DNA methylation landscape of advanced prostate cancer

Whole-genome bisulfite sequencing along with whole-genome and transcriptome sequencing of 100 prostate cancer metastases identifies genomic regions that are differentially methylated during disease progression and a novel epigenomic subtype.

Shuang G. Zhao
William S. Chen
Felix Y. Feng
Research13 Jul 2020
Nature Genetics

Volume: 52, P: 778-789
A community-based model of rapid autopsy in end-stage cancer patients

Kathryn Alsop
Heather Thorne
David D Bowtell
Correspondence12 Sept 2016
Nature Biotechnology

Volume: 34, P: 1010-1014
Switching and withdrawing hormonal agents for castration-resistant prostate cancer

The antiandrogen withdrawal syndrome (AAWS) is characterized by tumour regression on treatment discontinuation. Here, the mechanisms of AAWS and the development of treatment resistance are described, and the implications for the development of novel drugs and the challenges associated with redefining the utility of older treatments are discussed.

David Lorente
Joaquin Mateo
Johann S. de Bono
Reviews07 Jan 2015
Nature Reviews Urology

Volume: 12, P: 37-47
Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Thymic epithelial tumors are associated with increased risk of immune checkpoint inhibitor (ICI)-induced myotoxicities, and the presence of anti-acetylcholine-receptor antibodies has the potential to serve as a biomarker for ICI-induced myocarditis in patients with cancer.

Charlotte Fenioux
Baptiste Abbar
Joe-Elie Salem
Research26 Oct 2023
Nature Medicine

Volume: 29, P: 3100-3110
Author Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Charlotte Fenioux
Baptiste Abbar
Joe-Elie Salem
Amendments and Corrections27 Nov 2023
Nature Medicine

Volume: 29, P: 3268
Publisher Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Charlotte Fenioux
Baptiste Abbar
Joe-Elie Salem
Amendments and Corrections03 Jan 2024
Nature Medicine

Volume: 30, P: 910
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab

Helen Gogas
Shruthi Ravimohan
Céleste Lebbé
ResearchOpen Access19 Jul 2024
npj Precision Oncology

Volume: 8, P: 1-13
Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss

Javier Octavio Mejía-Hernández
Simon P. Keam
Sue Haupt
ResearchOpen Access08 Sept 2022
Cell Death & Disease

Volume: 13, P: 1-17
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

Joaquin Mateo
David Olmos
Patrick Schöffski
ResearchOpen Access22 Mar 2016
British Journal of Cancer

Volume: 114, P: 889-896

Search

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Envisioning the future of early anticancer drug development

Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer

Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer

Unravelling mutational signatures with plasma circulating tumour DNA

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology

Copy number architectures define treatment-mediated selection of lethal prostate cancer clones

Spatial analysis with SPIAT and spaSim to characterize and simulate tissue microenvironments

Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling

The DNA methylation landscape of advanced prostate cancer

A community-based model of rapid autopsy in end-stage cancer patients

Switching and withdrawing hormonal agents for castration-resistant prostate cancer

Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Author Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Publisher Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab

Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

Search

Quick links

Search

Filter By:

Search

Quick links